Are CV studies worth it for diabetes meds? After Merck and Sanofi's recent successes, some say no

Earlier this week, diabetes drugmakers Merck ($MRK) and Sanofi ($SNY) rolled out data showing their meds--Januvia and Lyxumia, respectively--passed heart safety tests, turning up no red flags in postmarketing studies. And now, some industry watchers are wondering whether those large, expensive trials--which aren't long enough to establish long-term outcomes--were worth it. Story | More on Januvia | More on Lyxumia